Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3–<36 months

Mocroft A. , Ledergerber B. , Katlama C. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22–29.

Murphy E.L. , Collier A.C. , Kalish L.A. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135: 17–26.

Paterson D.L. , Swindells S. , Mohr J. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21–30.

Chi B.H. , Cantrell R.A. , Zulu I. Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia. Int J Epidemiol 2009; 38: 746–756.

Montaner J.S. , Reiss P. , Cooper D. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. JAMA 1998; 279: 930–937.

Gibb D.M. , Goodall R.L. , Giacomet V. , McGee L. , Compagnucci A. , Lyall H. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Pediatr Infect Dis J 2003; 22: 56–62.

Pontali E. Facilitating adherence to highly active antiretroviral therapy in children with HIV infection: what are the issues and what can be done? Paediatr Drugs 2005; 7: 137–149.

Reddington C. , Cohen J. , Baldillo A. Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatr Infect Dis J 2000; 19: 1148–1153.

Stone V.E. , Jordan J. , Tolson J. , Miller R. , Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 2004; 36: 808–816.

Maitland D. , Jackson A. , Osorio J. , Mandalia S. , Gazzard B.G. , Moyle G.J. Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy. HIV Med 2008; 9: 667–672.

Molina J.M. Efficacy and safety of once-daily regimens in the treatment of HIV infection. Drugs 2008; 68: 567–578.

Maggiolo F. , Ripamonti D. , Arici C. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials 2002; 3: 371–378.

Portsmouth S.D. , Osorio J. , McCormick K. , Gazzard B.G. , Moyle G.J. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med 2005; 6: 185–190.

LePrevost M. , Green H. , Flynn J. Adherence and acceptability of once daily lmivudine and abacavir in human immunodeficiency virus type-1 infected children. Pediatr Infect Dis J 2006; 25: 533–537.

Moyle G.J. , DeJesus E. , Cahn P. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr 2005; 38: 417–425.

DeJesus E. , McCarty D. , Farthing C.F. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis 2004; 39: 411–418.

Bergshoeff A. , Burger D. , Verweij C. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir Ther 2005; 10: 239–246.

King J.R. , Kimberlin D.W. , Aldrovandi G.M. , Acosta E.P. Antiretroviral pharmacokinetics in the paediatric population: a review. Clin Pharmacokinet 2002; 41: 1115–1133.

Johnson M.A. , Moore K.H. , Yuen G.J. , Bye A. , Pakes G.E. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999; 36: 41–66.

Yuen G.J. , Weller S. , Pakes G.E. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet 2008; 47: 351–371.

Verweij-van Wissen C.P. , Aarnoutse R.E. , Burger D.M. Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 816: 121–129.

Moyle G. , Boffito M. , Fletcher C. Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2009; 53: 1532–1538.

Yuen G.J. , Lou Y. , Bumgarner N.F. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother 2004; 48: 176–182.

Johnson V.A. , Brun-Vezinet F. , Clotet B. Update of the drug resistance mutations in HIV-1: spring 2008. Top HIV Med 2008; 16: 62–68.

Jullien V. , Urien S. , Chappuy H. Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis. J Clin Pharmacol 2005; 45: 257–264.

Jullien V. , Treluyer J.M. , Chappuy H. Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients. Br J Clin Pharmacol 2005; 59: 183–188.

Burger D.M. , Verweel G. , Rakhmanina N. Age-dependent pharmacokinetics of lamivudine in HIV-infected children. Clin Pharmacol Ther 2007; 81: 517–520.

Tremoulet A.H. , Capparelli E.V. , Patel P. Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants. Antimicrob Agents Chemother 2007; 51: 4297–4302.

Musiime V. , Ferrier A. , Kitaka S.B. Pharmacokinetics of once versus twice daily lamivudine and abacavir in HIV-1 infected Ugandan children in the ARROW trial. 5th IAS Conference on HIV Pathogenesis. 19–22 July 2009, Cape Town, South Africa. Abstract WEPEB271.

Violari A. , Cotton M.F. , Gibb D.M. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359: 2233–2244.

PENTA Steering Committee. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 2009; 10: 591–613.

Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. US Department of Health and Human Services (Updated 23 February 2009. Accessed 17 June 2009.) Available from http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf.